Oncotarget: Cell cycle arrest and anaphase catastrophe in malignant T-cells

Oncotarget published “NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells” which reported that peripheral T-cell lymphoma is characterized by poor outcomes.

Here, the authors report that PTCL is characterized by an increased rate of chromosomal instability. They identified p27Kip1 as a mediator of anaphase catastrophe in these cells.

Dr. Alexey V. Danilov from The City of Hope Comprehensive Cancer Center said, “Peripheral T-cell lymphoma (PTCL) is an aggressive subset of non-Hodgkin lymphomas (NHL) characterized by poor outcomes.“

Aberrant T-cell receptor and JAK-STAT signaling, genomic abnormalities targeting epigenetic modifiers and chromatin remodeling and altered cellular metabolism result in deregulated cell cycle, enhanced cell survival and proliferation in PTCL. The substantial genetic and biologic heterogeneity hinders success of targeted therapies in this disease and chemotherapy remains standard in both de novo and relapsed/refractory settings.

This pathway preferentially eliminates aneuploid cancer cells by antagonizing clustering of supernumerary centrosomes during mitosis, forcing cells to undergo multipolar divisions. However, it is not known if anaphase catastrophe occurs in NHL cells, and whether it may be induced by pharmacologic induction of endogenous CDK inhibitors in a cell.

Pevonedistat forms a covalent adduct with NEDD8, resulting in NAE inhibition and accumulation of CRL substrates. CDT1, CDK inhibitors p21Cip1/p27Kip1 as well as checkpoint kinase Wee1 are among the CRL substrates which are increased following NAE inhibition.

The Danilov Research Team concluded in their Oncotarget Research Output, “we demonstrate that PTCL exhibits pronounced chromosomal mis-segregation. Targeting NAE with pevonedistat leads to cell cycle arrest and anaphase catastrophe in neoplastic T-cells. This effect, possibly coupled with immunomodulatory activity of pevonedistat recently described by our group [18], justifies continued exploration of pevonedistat as a novel therapeutic approach in T-cell NHL.“

Sign up for free Altmetric alerts about this article

DOI – https://doi.org/10.18632/oncotarget.28063

Full text – https://www.oncotarget.com/article/28063/text/

Correspondence to – Alexey V. Danilov – [email protected]

Keywords – pevonedistat, T-cell lymphoma, chromosomal instability, anaphase catastrophe

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud – https://soundcloud.com/oncotarget
Facebook – https://www.facebook.com/Oncotarget/
Twitter – https://twitter.com/oncotarget
LinkedIn – https://www.linkedin.com/company/oncotarget
Pinterest – https://www.pinterest.com/oncotarget/
Reddit – https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
[email protected]
18009220957×105

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC